JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
Read original at benzingaStocks · News reference
Leerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $17
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises the price target from $11 to $17.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 9:22 AM
- Checked
- Aug 4, 2026, 9:22 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing
Read original at benzinga8-K filing — Replimune Group, Inc. (REPL)
Filed: 2026-08-14 AccNo: 0001104659-26-096483 Size: 266 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarReplimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from
Read original at benzinga